Clinical Trial Detail

NCT ID NCT00089245
Title Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Y-mAbs Therapeutics
Indications

medulloblastoma

Ewing sarcoma

rhabdoid cancer

neuroblastoma

Advanced Solid Tumor

Therapies

Omburtamab I-131

Age Groups: adult child senior

No variant requirements are available.